Abstract
Over half the world’s population is at risk for viruses transmitted by Aedes mosquitoes, such as, dengue and Zika. The primary vector, Aedes aegypti, thrives in urban environments. Despite decades of effort, cases and geographic range of Aedes-borne viruses (ABV) continue to expand. Rigorously proven vector control interventions that measure protective efficacy against ABV diseases is limited to Wolbachia in a single trial in Indonesia, and do not include any chemical intervention. Spatial repellents, a new option for efficient deployment, are designed to decrease human exposure to ABV by releasing active ingredients into the air that disrupt mosquito-human contact. A parallel, cluster-randomized controlled trial was conducted in Iquitos, Peru to quantify the impact of a transfluthrin-based spatial repellent on human ABV infection. From 2,907 households across 26 clusters (13 per arm), 1,578 participants were assessed for seroconversion (primary endpoint) by survival analysis. Incidence of acute disease was calculated among 16,683 participants (secondary endpoint). Adult mosquito collections were conducted to compare Ae. aegypti abundance, blood-fed rate and parity status through mixed effect difference-in-difference analyses. The spatial repellent significantly reduced ABV infection by 34·1% (1-sided 95% CI lower limit, 6·9%; 1-sided p-value=0·0236, z=1·98). Aedes aegypti abundance and blood-fed rates were significantly reduced by 28·6% (95% CI 24·1%, ∞); z=-9·11) and 12·4% (95% CI 4·2%, ∞); z=-2·43), respectively. Our trial provides the first conclusive statistical evidence from a pre-planned cluster randomized controlled clinical trial with a pre-defined effect size on the primary endpoint that was appropriate powered to prospectively quantify and statistically test for a difference in the impact of a chemical intervention, in this case a spatial repellent, to reduce the risk of ABV transmission compared to a placebo.
Significance Statement Vector interventions are needed for Aedes-borne viral diseases (dengue, Zika, chikungunya, and yellow fever) prevention, but their application is hindered by the lack of evidence proving they prevent infection or disease. Our research reports the first conclusive statistical evidence from a pre-planned, prospective cluster-randomized, controlled clinical trial (cRCT) of significant protective efficacy (34.1% hazard estimate) against human Aedes-borne virus (ABV) infection by a chemical-based vector control intervention, the most commonly used intervention category among all ABV World Health Organization recommendations. A previous trial against malaria in Indonesia indicated a positive trend but did not detect a significant effect. Results from our ABV study will help guide public health authorities responsible for operational management and world-wide prevention of ABV, and incentivize new strategies for disease prevention.
Competing Interest Statement
Authors report grants from Bill and Melinda Gates Foundation, non-financial support from SC Johnson, A Family Company, during the conduct of the study.
Clinical Trial
NCT03553277
Funding Statement
This study was funded by the Bill and Melinda Gates Foundation (BMGF) to the University of Notre Dame (Grant# OPP1081737). Further support was provided by the Defense Threat Reduction Agency (DTRA), Military Infectious Disease Research Program (MIDRP, S0520_15_LI and S0572_17_LI), and the U.S. National Institute of Allergy and Infectious Diseases (NIH/NIAID) award number P01 AI098670. SC Johnson used internal company financial resources for the development, manufacturing, delivery, and shipment of the intervention (SR and placebo) used in the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study protocol (#NAMRU6.2014.0021, Supplementary Information (SI)) was approved by the U.S. Naval Medical Research Unit No. 6 (NAMRU-6) Institutional Review Board (IRB), which includes Peruvian representation and complies with US Federal and Peruvian regulations governing the protections of human subjects, and the Regional Health Authority (DIRESA), the local branch of the Peruvian Ministry of Health. IRB authorization agreements were established between the NAMRU-6, the University of Notre Dame (Sponsor), the University of California at Davis, and the University of Washington.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure Statement: Approved for Public Distribution
Competing Interest Statement: The authors have declared that no competing interests exist.
Copyright statement: SAJ, WRC, EJA and RDH are military service members and ACM, HA, CG, IB, CS, GMV, KE, CF, AAH, and MES are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright protection under this Title is not available for any work of the United States Government”. Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties.
Disclaimer: The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.
The revised manuscript: 1) has been adapted to a new format template, 2) has been edited for clarity regarding selection of the spatial repellent intervention, 3) includes a more detailed and prominent justification of the use of one-sided confidence intervals and focuses the presentation of results on these results in the abstract and main manuscript, 4) includes additional text on adverse events and post-intervention entomological findings in the discussion, and 5) includes additional text in the supplemental information about previous work with spatial repellents for malaria. The principal purpose of our manuscript is to publish the primary analysis from this large trial. In our revision, we continued to focus the manuscript on primary results. It is our intention to publish additional articles based on secondary and tertiary analyses. For that reason, in this manuscript we did not include secondary analyses, except to highlight changes in indoor Aedes aegypti adult female populations after the spatial repellent intervention was stopped.
Data Availability
De-identified analytical datasets and statistical codes will be made available upon pre-print posting. The data will be made available without investigator support to anyone requesting the data and distributed under the terms of the Creative Commons Attribution (CC-BY) License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Requests for analytical datasets and statistical codes should be sent to bcreiner{at}uw.edu.
